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ABSTRACT
Hydroxychloroquine is an antimalarial drug used in many rheumatologic and systemic diseases. Although considered by clinicians to be 
relatively safe, serious side effects have been documented (retinotoxicity, neuromyotoxicity and cardiotoxicity). 
We present the case of a 41-year-old woman with systemic lupus erythematosus (SLE) who presented at our institution with acute heart 
failure after taking hydroxychloroquine for a period of 3 months. An endomyocardial biopsy ruled out myocarditis related to systemic 
lupus erythematosus but demonstrated pathological changes related to hydroxychloroquine toxicity. It is exceptional to observe such 
cardiac toxicity after such a low cumulative dose (16 grams). The potential severity and reversibility of this complication underscores the 
importance of a high level of suspicion and timely diagnosis.
LEARNING POINTS
• Since the use of hydroxychloroquine in systemic lupus erythematosus (SLE) patients is increasing, clinicians should be alert to the 
development of antimalarial cardiotoxicity during treatment. 
• In general, hydroxychloroquine myocardial toxicity should be suspected in all patients with cardiac complaints; new onset of heart 
failure or conduction abnormalities who received high cumulative dose; however, exceptionally, it can also be observed in SLE patients 
with lower doses after shorter periods of time. 
• The potential reversibility of cardiotoxicity after antimalarial drug suppression is possible thanks to a rapid and accurate diagnosis, 
which is important for assuring appropriate management of the condition.
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INTRODUCTION
Hydroxychloroquine and chloroquine are antimalarial drugs extensively used in the long-term treatment of many rheumatologic and 
systemic diseases[1]. The most common side effects reported have been nausea, stomach cramps and diarrhea. After prolonged treatment, 
other side effects can appear. Cardiac toxicity due to hydroxychloroquine is a very rare complication, with cardiac conduction abnormalities 
the most reported adverse effects associated with this complication. Serious life-threatening infiltrative cardiomyopathy has also been 
reported in very few cases; thus, to date, the host factors that contribute to cardiotoxicity remain unclear. Some authors have suggested 
that a high cumulative dose could be the main risk factor of such toxicity[2,3].
CASE REPORT
A 41-year-old woman with systemic lupus erythematosus (SLE) was admitted to the hospital because of one month-history of shortness 
of breath, orthopnea and legs edema. Eight years prior to admission, the patient was diagnosed with autoimmune hepatitis and primitive 
biliary cirrhosis (overlap syndrome), receiving ursodesoxicolic acid (700mg/d) with satisfactory clinical and analytical response. One year 
prior to admission, the patient was diagnosed with SLE after presenting legs and eyelids edema, recurrent joint pain and skin lesions on sun-
exposed areas. A renal biopsy revealed type V lupus glomerulonephritis. In accordance, the patient began taking oral prednisone (50mg/d) 
with an apparent clinical improvement but the persistence of proteinuria (>7g/d) lead her nephrologist to then prescribe mycophenolate 
European Journal
of Case Reports in
Internal Medicine
DOI: 10.12890/2015_000204 European Journal of Case Reports in Internal Medicine © EFIM 2015
followed by tacrolimus with no proteinuria improvement. Three months prior to admission, in addition to prednisone, mycophenolate and 
tacrolimus, the patient started hydroxychloroquine for the persistence of skin lesions.
After three months of hydroxicloroquine treatment, the patient was seen at the emergency department for a one-month gradual 
presentation of legs edema, orthopnea and paroxysmal nocturnal dyspnea. She had no prior history of lung or cardiovascular diseases. On 
admission, a physical examination, medical history check and chest X-ray confirmed signs of congestive heart failure without hemodynamic 
instability. The blood analysis was normal; hepatic and renal function indices were normal and the cardiac markers curve was negative. The 
electrocardiogram showed sinus rhythm with a right bundle branch block without ischemic signs. 
With the suspicion of acute biventricular heart failure related to SLE, diuretics, vasodilatadors and high doses of prednisone were started, 
while hydroxychloroquine was stopped, in anticipation of further testing. During admission, laboratory tests revealed normal levels of 
Acute-phase proteins, elevated ProBNP (8959ng/L) and low albumin (26g/L). All the antibodies and complement titres were within normal 
limits. A transthoracic echocardiography and cardiac magnetic resonance imaging (CMR) showed moderate left ventricular dilatation with 
eccentric hypertrophy, severe left ventricular systolic dysfunction (LVEF of 28%) with global left ventricle (LV) hypokinesia and complete 
lateral akinesia. The right ventricle’s function was normal. Myocardial edema was not found. Amyloidosis was ruled out by abdominal fat 
aspiration biopsy. Fifteen days after admission, a cardiac catheterization did not demonstrate coronary artery disease and an endomyocardial 
biopsy was performed. The biopsy specimen revealed the classic electron microscopic findings of myelin figures (myeloid bodies), which 
was highly suggestive of toxic myocardiopathy due to the hydroxychloroquine treatment; the biopsy findings, however, were not able to 
demonstrate the presence of curvilinear bodies.
Figure 1: Electron micrograph from right ventricular endomyocardium showing the 
presence of myeloid bodies.
Three months after discharge, a new transthoracic echocardiography and CMR showed the persistence of LV dilatation without any 
improvement of neither LV systolic dysfunction (LVEF of 30%), nor akinetic segments. Late gadolinium enhancement studies of both CMR 
support a diagnosis of nonischemic disease, while the absence of myocardial edema reasonably excludes myocarditis.
DISCUSSION
Cardiac involvement is one of the main complications contributing to the morbidity and mortality of patients suffering from SLE[4]. 
Involvement of any of the three layers of the heart — pericardium, myocardium and endocardium — have been demonstrated in more than 
50% of SLE patients, when very sensitive techniques for cardiovascular investigation were used[4]. When myocardial is affected, myocarditis 
is the most characteristic clinical feature, presenting in a range of 3% to 15% of SLE patients, though it appears to be much more common 
in autopsy studies, thus suggesting a subclinical nature of this complication. 
Cardiotoxicity caused by some drugs used for lupus treatment, especially antimalarial drugs (chloroquine/hydroxychloroquine), is among 
the other causes of serious cardiac affectation in SLE patients. Host factors that contribute to cardiotoxicity caused by antimalarial drugs 
still remain unclear, but it is well known that large cumulative doses raise the likelihood for toxic myocarditis. Two different forms of 
cardiac toxicity have been described in relation to antimalarial drugs, with the most frequently reported being those related to conduction 
abnormalities, such as incomplete or complete right and left bundle-branch block or atrioventricular block[4]. Much less frequently, 
infiltrative cardiomyopathy has also been occasionally described as a serious complication. 
Definitive diagnosis is provided by endomyocardial biopsy, revealing preserved myocardial architecture and a constellation of findings, 
including vacuolar myopathy, myeloid bodies and curvilinear bodies, which are considered the most specific findings when present. In 
spite of hydroxychloroquine withdrawal, the patient prognosis remains uncertain among the overall cases reported, varying from complete 
recovery to the need for cardiac transplantation, or death[5].
In our case, optic and electron microscopy ruled out SLE-related inflammatory cardiomyopathy and other storage cardiomyopathy. Also, 
CMR results excluded ischemic cardiomyopathy. Although curvilinear bodies could not be found in our patient’s endomyocardial biopsy, 
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the diagnosis was supported by the lack of inflammatory activity and the presence of granular inclusions as myeloid bodies on the electron 
microscopy. Interestingly, the particularity of our patient was the relative rapid onset of hydroxichloroquine cardiomyotoxicity after a 
3-month period of treatment and, subsequently, a relative low cumulative dose of hydroxychloroquine (16 grams). Our literature review 
showed only one previously reported similar case, involving a patient with recurrent malaria, who was treated repeatedly with chloroquine 
and presented myocardiotoxicity, with a similar low cumulative dosage of 15 grams[6]. 
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